Two-year Outcomes of Remission Induction Therapy with Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis: A Case Series. Suzuki S, Otani T, Nishi T, Ikeda K, et al. Intern Med 2026;65:1416-1420.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Suzuki S, Otani T, Nishi T, Ikeda K, et al. Two-year Outcomes of Remission Induction Therapy with Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis: A Case Series. Intern Med 2026;65:1416-1420.
PMID: 41125369